1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.89%
Cash & equivalents declining -7.89% while Biotechnology shows 0.00% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-7.89%
Cash + STI yoy growth ≥ 1.5x the Biotechnology median of -2.48%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.62%
Current assets growth ≥ 1.5x the Biotechnology median of -0.43%. Joel Greenblatt sees a potential liquidity edge if well allocated.
-4.83%
PP&E growth below half of Biotechnology median of 0.00%. Jim Chanos would suspect potential underinvestment or strategic shift away from core assets.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3.38%
Below half the Biotechnology median of 0.00%. Jim Chanos sees a sharp divergence from peers, possibly a sign of strategic retreat or capital shortage.
No Data
No Data available this quarter, please select a different quarter.
-7.59%
Below half the Biotechnology median of 0.00%. Jim Chanos might see potential stagnation or distress vs. peers.
-25.56%
Payables growth above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
-49.71%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
No Data
No Data available this quarter, please select a different quarter.
240.62%
≥ 1.5x the Biotechnology median of 0.00%. Joel Greenblatt sees a robust subscription base vs. peers.
-18.75%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
-24.27%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects potential working capital strain.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-24.27%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects an alarming rise in overall leverage.
5.27%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
-5.68%
≥ 1.5x Biotechnology median of -2.14%. Joel Greenblatt sees stronger retained profit growth vs. peers.
-17.53%
Above 1.5x Biotechnology median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
No Data
No Data available this quarter, please select a different quarter.
-4.86%
≥ 1.5x Biotechnology median of -1.70%. Joel Greenblatt sees stronger equity growth vs. peers.
-7.59%
≥ 1.5x Biotechnology median of -0.10%. Joel Greenblatt sees more aggressive expansions than peers.
No Data
No Data available this quarter, please select a different quarter.
-49.71%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
7.55%
Above 1.5x Biotechnology median 1.55%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.